Featured Research

from universities, journals, and other organizations

Estrogen receptor status of HER2+ breast cancer correlates with response to anti-HER therapies

Date:
May 6, 2010
Source:
European Society for Medical Oncology
Summary:
An international team of researchers has discovered molecular evidence that may explain why some women with HER2 over-expressing breast cancer do not respond to drugs designed to target this important molecule.

An international team of researchers has discovered molecular evidence that may explain why some women with HER2 over-expressing breast cancer do not respond to drugs designed to target this important molecule.

The research, presented at the IMPAKT Breast Cancer Conference in Brussels, Belgium, could have an important impact on future clinical trial design and treatment strategies in HER2 over-expressing breast cancer.

The over-expression of HER2 --a molecule found on the surface of cells-- is an important marker in breast cancer. It had been associated with a poor outcome for women, but with the advent of anti-HER2 targeted agents, the prognosis for these women has improved.

But oncologists have known for some time that some HER2 over-expressing (HER2+) breast cancers do not respond to trastuzumab, currently the most commonly prescribed anti-HER2 agent.

Belgian and US researchers led by Dr Sherene Loi from the Institute Jules Bordet in Brussels set out to determine whether estrogen receptor status, another major biological variable in breast cancer, was involved.

"We looked at HER2+ breast cancer using gene expression data, array comparative genomic hybridization, cell lines and clinical data from nealry 2000 patients to determine if estrogen-receptor status plays a significant part in the biology of HER2+ breast cancer and response to anti-HER2 therapies," said Dr Loi.

"We found that estrogen receptor status of HER2+ breast cancer seems to be correlated with different responses to anti-HER therapies. Currently, the biological differences in the group of breast cancers that overexpress HER2 are largely unknown."

The results show that patients with ER+/HER2+ compared with ER-/HER2+ breast cancers may actually benefit more from drugs that inhibit the PI3K/AKT molecular pathway, as this could be the dominant biological pathway for tumor growth and progression, the researchers say.

"In contrast, our data suggest that inhibition of estrogen receptor --alone and in combination with such an inhibitor -- could actually result in a worse outcome for the patient," Dr Loi adds. "This may help explain why researchers saw such a poor outcome in clinical trials where women with HER2+ cancer were given hormonal therapy alone."


Story Source:

The above story is based on materials provided by European Society for Medical Oncology. Note: Materials may be edited for content and length.


Cite This Page:

European Society for Medical Oncology. "Estrogen receptor status of HER2+ breast cancer correlates with response to anti-HER therapies." ScienceDaily. ScienceDaily, 6 May 2010. <www.sciencedaily.com/releases/2010/05/100506112557.htm>.
European Society for Medical Oncology. (2010, May 6). Estrogen receptor status of HER2+ breast cancer correlates with response to anti-HER therapies. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/05/100506112557.htm
European Society for Medical Oncology. "Estrogen receptor status of HER2+ breast cancer correlates with response to anti-HER therapies." ScienceDaily. www.sciencedaily.com/releases/2010/05/100506112557.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins